Avalide: Comprehensive Blood Pressure Control in One Tablet
Avalide
| Product dosage: 162.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.20 | $66.00 (0%) | 🛒 Add to cart |
| 60 | $1.67 | $132.00 $100.00 (24%) | 🛒 Add to cart |
| 90 | $1.48 | $198.00 $133.00 (33%) | 🛒 Add to cart |
| 120 | $1.38 | $264.00 $166.00 (37%) | 🛒 Add to cart |
| 180 | $1.29 | $396.00 $233.00 (41%) | 🛒 Add to cart |
| 270 | $1.23
Best per pill | $594.00 $333.00 (44%) | 🛒 Add to cart |
Synonyms | |||
Avalide combines two proven antihypertensive agents—irbesartan and hydrochlorothiazide—into a single, convenient tablet designed for patients requiring multiple medications to achieve blood pressure targets. This fixed-dose combination leverages the complementary mechanisms of an angiotensin II receptor blocker (ARB) and a thiazide diuretic to provide synergistic effects on hypertension management. Clinical studies demonstrate superior efficacy compared to monotherapy, with a well-tolerated side effect profile. Ideal for patients whose blood pressure remains uncontrolled on single-agent therapy, Avalide simplifies treatment regimens while optimizing cardiovascular protection.
Features
- Contains irbesartan (150 mg or 300 mg) and hydrochlorothiazide (12.5 mg)
- Dual mechanism: ARB blocks angiotensin II receptors; thiazide diuretic promotes sodium/water excretion
- Once-daily dosing for consistent 24-hour coverage
- Available in multiple strength combinations for individualized titration
- Film-coated tablets for ease of swallowing
- Manufactured under strict pharmaceutical quality standards
Benefits
- Achieves significant systolic and diastolic blood pressure reduction through complementary mechanisms
- Reduces pill burden compared to taking two separate medications
- Lowers risk of dose-dependent side effects through optimized combination dosing
- Provides continuous 24-hour blood pressure control with once-daily administration
- May improve medication adherence through simplified treatment regimen
- Offers flexible dosing options to accommodate individual patient needs
Common use
Avalide is indicated for the treatment of hypertension, either as initial therapy for patients likely to need multiple drugs to achieve blood pressure goals, or as replacement therapy for patients already stabilized on the individual components. It is particularly suitable for patients with hypertension inadequately controlled with monotherapy, those with volume overload components, or individuals requiring more aggressive blood pressure management to reduce cardiovascular risk. The combination may be especially beneficial for patients with certain comorbid conditions where both RAAS inhibition and diuresis are desirable.
Dosage and direction
The recommended starting dose is Avalide 150/12.5 (irbesartan 150 mg/hydrochlorothiazide 12.5 mg) taken orally once daily. For patients insufficiently controlled on this dosage after 2-4 weeks, the dose may be increased to Avalide 300/12.5. For patients previously stabilized on irbesartan 300 mg monotherapy who require additional blood pressure reduction, Avalide 300/12.5 may be initiated. Maximum recommended daily dose is irbesartan 300 mg/hydrochlorothiazide 25 mg. Administration may be taken with or without food, preferably at the same time each day to maintain consistent therapeutic levels. Dose titration should be based on blood pressure response and tolerability.
Precautions
Monitor renal function and electrolytes periodically, particularly in patients with impaired renal function, those on nonsteroidal anti-inflammatory drugs, or elderly patients. Assess serum potassium levels, especially in patients with renal impairment, diabetes, or those taking potassium supplements or potassium-sparing diuretics. Observe for signs of fluid or electrolyte imbalance including hyponatremia, hypochloremic alkalosis, and hypokalemia. Use caution in patients with impaired hepatic function or progressive liver disease. Monitor for worsening renal function in susceptible patients. Photosensitivity reactions may occur; advise appropriate sun protection. Orthostatic hypotension may occur, particularly in volume-depleted patients.
Contraindications
Avalide is contraindicated in patients with known hypersensitivity to any component of this product or other sulfonamide-derived drugs. Do not use in patients with anuria or severe renal impairment (CrCl <30 mL/min). Contraindicated in pregnancy due to potential for fetal harm, particularly during the second and third trimesters. Avoid use in patients with refractory hypokalemia, hypercalcemia, or clinically significant hepatic impairment. Not recommended for patients with history of angioedema related to previous ACE inhibitor or ARB therapy.
Possible side effects
Common adverse reactions (≥2%) include dizziness, fatigue, musculoskeletal pain, nausea/vomiting, and hyperkalemia. Less frequent side effects may include orthostatic hypotension, increased blood urea nitrogen, elevated serum creatinine, electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia, hypercalcemia), hyperuricemia, gout, impaired glucose tolerance, rash, and photosensitivity reactions. Rare but serious adverse effects include angioedema, acute renal failure, pancreatitis, hepatic impairment, and blood dyscrasias. Most side effects are dose-dependent and often diminish with continued therapy or dose adjustment.
Drug interaction
Concomitant use with other RAAS-acting agents (ACE inhibitors, aliskiren) increases risk of hypotension, hyperkalemia, and renal impairment. NSAIDs may reduce antihypertensive effect and increase risk of renal impairment. Lithium levels may increase due to reduced renal clearance. Corticosteroids and ACTH may enhance electrolyte depletion. Alcohol, barbiturates, or narcotics may potentiate orthostatic hypotension. Diabetic therapeutic requirements may be altered. Cholestyramine and colestipol may reduce hydrochlorothiazide absorption. May potentiate effects of neuromuscular blocking agents. May decrease arterial responsiveness to norepinephrine.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If it is near the time for the next dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed dose. Consistent daily administration is important for maintaining blood pressure control. Patients should be advised to establish a routine for medication administration to minimize missed doses.
Overdose
Symptoms of overdose may include hypotension, tachycardia, bradycardia, dizziness, decreased urinary output, electrolyte disturbances, and renal impairment. The most likely manifestation of overdose would be hypotension and electrolyte abnormalities. Treatment should be supportive and symptomatic. Gastric lavage may be considered if ingestion is recent. IV normal saline may be administered for hypotension. Electrolyte imbalances and renal function should be monitored and corrected appropriately. Irbesartan is not dialyzable, while hydrochlorothiazide is eliminated by hemodialysis.
Storage
Store at controlled room temperature 20°-25°C (68°-77°F) with excursions permitted between 15°-30°C (59°-86°F). Keep container tightly closed and protect from moisture and light. Keep out of reach of children. Do not use if the blister pack is damaged or shows signs of tampering. Discard any unused medication properly according to local regulations, preferably through medication take-back programs.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment decisions should be made by qualified healthcare professionals based on individual patient circumstances. Patients should not alter their medication regimen without consulting their physician. The prescribing information provided here may not include all possible uses, directions, precautions, or interactions. Always refer to the official prescribing information for complete details.
Reviews
Clinical trials demonstrate Avalide provides superior blood pressure reduction compared to component monotherapies, with mean additional reductions of 5-10 mmHg systolic and 3-6 mmHg diastolic. Physicians report high patient satisfaction due to simplified dosing and improved adherence. Many patients note better overall blood pressure control with fewer side effects compared to previous multiple medication regimens. Long-term studies show consistent efficacy maintained over 12 months of treatment with stable safety profile. Healthcare providers appreciate the flexibility of multiple strength options for individualized titration.